Please login to the form below
omecamtiv
This page shows the latest omecamtiv news and features for those working in and with pharma, biotech and healthcare.
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The announcement comes just a month after the US Food and Drug Administration declined to approve Cytokinetics' heart failure drug omecamtiv mecarbil, with the regulator requesting results from an additional clinical
Latest news
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
The results from the GALACTIC-HF study show that treatment with the drug, omecamtiv mecarbil, hit the primary endpoint of statistical significance on a measure of reduction in hospitalisation or other ... Omecamtiv mecarbil, originally developed by
-
Trial of Amgen, Servier’s heart failure drug clears interim check
Drug could become a $2bn product if approved. Amgen and Servier are creeping closer to a readout on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their phase ... GALACTIC-HF should be sufficient to support approval of
-
FDA fast-tracks Jardiance for heart failure review
Other contenders looking to meet the needs of heart failure patients include Amgen and Servier, whose omecamtiv mecarbil, recently passed a futility review in its phase 3 study.
-
Servier begins construction of new R&D hub in Paris
In its late-stage pipeline, Servier and partner Amgen have heart failure candidate omecamtiv mecarbil advancing towards a pivotal phase 3 trial read out.
-
Amgen, Servier heart failure drug clears trial hurdle
Amgen and Servier have inched closer to a verdict on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their first phase 3 study passed a futility review. ... In the case of the GALACTIC-HF study of omecamtiv, the interim
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Heart failure therapy embarks on a new era
In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
-
Deal Watch table for July 2013
100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... rights in Europe for omecamtiv mecarbil. †
-
Pharma deals during July 2013
the US, and Servier receives an option to omecamtiv mecarbil for Europe. ... Omecamtiv mecarbil is currently in phase II trials for acute and chronic heart failure and is the most advanced drug candidate coming out of Amgen's collaboration with
-
Deal Watch table for June 2013
129. Cytokinetics / Amgen. Extension of existing licence to Japan. Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
